Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...

Antiasthma Drugs: Leukotriene Modifiers

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...

Drugs Used in Lower Respiratory Disorders: Overview

Drugs Used in Lower Respiratory Disorders: Overview

Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...

Asthma-IV: Diagnostic and Management

Asthma-IV: Diagnostic and Management

The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:

Asthma: Pathogenesis and Management

Asthma: Pathogenesis and Management

Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

[Biologic therapies in adult asthma].

La Revue du praticien·2025

Same author

Long-term effectiveness and safety of dupilumab in severe asthma: A 5-year real-world multicenter study.

The journal of allergy and clinical immunology. In practice·2025

Same author

Uncovering treatable traits in severe asthma: The role of cardiopulmonary exercise testing.

The journal of allergy and clinical immunology. In practice·2025

Same author

Diagnosis of Dysfunctional Breathing in Severe Asthma.

The journal of allergy and clinical immunology. In practice·2025

Same author

Severe asthma care trajectories: the French RAMSES cohort.

ERJ open research·2024

Same author

CT Imaging Assessment of Response to Treatment in Allergic Bronchopulmonary Aspergillosis in Adults With Bronchial Asthma.

Chest·2024

Search research articles

Related Experiment Video

Updated: Jul 10, 2026

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

[Targeted immunologic therapies for severe asthma].

Marc Humbert¹, Gilles Garcia, Pascal Chanez

¹Service de pneumologie et réanimation respiratoire, AP-HP, Hôpital Antoine Béclère, Université Paris Sud, F-92140 Clamart, France. marc.humbert@abc.aphp.fr

Presse Medicale (Paris, France : 1983)

|November 6, 2007

Summary

New asthma treatments targeting cellular mechanisms show disappointing results. While some therapies reduce inflammation, they fail to improve patient symptoms or bronchial hyperreactivity, highlighting the need for further research.

More Related Videos

Intralymphatic Immunotherapy and Vaccination in Mice

Intralymphatic Immunotherapy and Vaccination in Mice

Published on: February 2, 2014

Related Experiment Videos

Last Updated: Jul 10, 2026

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

Intralymphatic Immunotherapy and Vaccination in Mice

Intralymphatic Immunotherapy and Vaccination in Mice

Published on: February 2, 2014

Area of Science:

Pulmonology
Immunology
Pharmacology

Context:

Asthma pathogenesis research has identified numerous cellular and molecular targets for novel therapies.
Recent clinical trials have evaluated several of these new treatment strategies for asthma.
Despite a better understanding of asthma's mechanisms, translating this into effective treatments remains challenging.

Purpose:

To review the outcomes of recent clinical trials targeting novel molecular mechanisms in asthma.
To assess the efficacy and limitations of emerging asthma treatment strategies.
To highlight the current landscape of targeted therapies for difficult-to-control asthma.

Summary:

Parenteral anti-interleukin-5 antibodies reduced eosinophilic airway inflammation but did not improve asthma symptoms or bronchial hyperreactivity.
Open-label studies with anti-TNF alpha antibodies show potential but require placebo-controlled validation for efficacy.
Omalizumab, an anti-IgE monoclonal antibody, is the first targeted therapy approved for severe allergic asthma.

Impact:

Current targeted therapies face challenges in demonstrating clinical benefit beyond reducing specific inflammatory markers.
Further research and rigorous clinical trials are essential to validate promising asthma treatments.
The development of effective targeted therapies for severe asthma remains an ongoing area of clinical investigation.